Verrica Pharmaceuticals

是其中之一......

• Russell 3000;
• TOB Iconic 10,000.

Verrica Pharmaceuticals 是一家在股票代码 VRCA (US) 下上市的公司。

查看带有其 14 名主要高管的组织结构图

Verrica Pharmaceuticals 搜索最多的简介

• Jayson Rieger, Chief Executive Officer
• Sean Stalfort, Director
• Lawrence Eichenfield, Director

高管在Verrica Pharmaceuticals变化

• Jayson Rieger已作为Chief Executive Officer加入公司  (新闻发布的2024十一月5号).
• John Kirby已作为Interim Chief Financial Officer加入公司  (新闻发布的2024十一月5号).

创建提醒
跟踪 Verrica Pharmaceuticals 的高管变动

Verrica Pharmaceuticals 拥有 1,840 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。

Popular M&A news in 药店

• Recursion Pharma and Exscientia have merged  (公布2024十一月27号)..
• Stemtech and Seacret Direct have announced they will merge  (公布2024十一月22号)..
• BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).

药店 行业的其他推荐联系人

• Sanofi 企业 Julie Van Ongevalle - Executive Vice President and Head of Consumer Healthcare
• Amneal Pharmaceuticals 企业 Paul Meister - Chairman of the Board
• Braeburn Pharmaceuticals 企业 Seth Harrison - Chairman and Director

了解更多有关药店行业的信息 >

Verrica Pharmaceuticals 的最新新闻稿

• Verrica Announces Pricing of $42.0 Million Public Offering - Verrica Pharmaceuticals
• Press Releases - Verrica Pharmaceuticals
• Verrica Announces Proposed Public Offering - Verrica Pharmaceuticals
• Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition - Verrica Pharmaceuticals
• Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP 315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference - Verrica Pharmaceuticals
• Verrica Pharmaceuticals Announces Restructuring of Commercial Organization - Verrica Pharmaceuticals
• Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York - Verrica Pharmaceuticals
• Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results - Verrica Pharmaceuticals
• Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP 315 an Investigational Oncolytic Peptide Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma - Verrica Pharmaceutica
• Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP 315 for the Treatment of Basal Cell Carcinoma on August 14 2024 - Verrica Pharmaceuticals
• View more press releases Close

关于 Verrica Pharmaceuticals 的社交媒体

• Verrica Pharmaceuticals 在 维基百科、谷歌新闻 和 雅虎财经
• Verrica Pharmaceuticals 在 LinkedIn、叽叽喳喳 和 YouTube

通过电子邮件联系联系该企业高管，包括 Lawrence Eichenfield

致电Verrica Pharmaceuticals，电话：+1 484...

查看组织结构图

Register to receive your alert

报告错误